Raymond James maintains Outperform rating on Zimmer Biomet with new PT of $113.

Raymond James maintains Outperform rating on Zimmer Biomet with new PT of $113.

Zimmer Biomet Holdings, Inc. (ZBH) has seen a significant upgrade in its stock rating from Raymond James, which has raised its price target to $113 from a previous $91. This move comes amidst strong financial performance and strategic growth initiatives.

In its latest earnings report for the second quarter of 2025, Zimmer Biomet reported robust earnings, with adjusted earnings per share (EPS) of $2.07, up 3% year over year, beating Street estimates of $1.99 [1]. The company's revenue reached $2.08 billion, a 7% year-on-year increase, surpassing analyst estimates of $2.05 billion [2]. This performance was driven by accelerating demand for hip and knee implants, bolstering the company's full-year adjusted profit forecast.

Despite the strong quarter, UBS maintains a Sell rating on ZBH, raising its price target to $96 from $91 [3]. UBS analysts cited the company's structural tailwinds, high interest rates, and trade tensions as reasons for their cautious outlook. However, Raymond James' upgrade reflects a more optimistic view on Zimmer Biomet's prospects.

Looking ahead, Zimmer Biomet expects revenue to grow 7.8% over the next 12 months, above the sector average and implying better top-line performance from newer products and services [2]. The company's acquisition of Paragon 28 and Monogram Technologies, along with its focus on innovation and technological advancements, positions it for future growth opportunities [1][4].

References:
[1] https://stockanalysis.com/stocks/zbh/
[2] https://finance.yahoo.com/news/zimmer-biomet-nyse-zbh-exceeds-181404625.html
[3] https://www.ubs.com/
[4] https://www.medicaldevice-network.com/news/zimmer-biomet-raises-2025-outlook-amid-strong-portfolio-growth/